sponsored
PatientsVille.com Logo

PatientsVille

Piperacillin Sodium And Tazobactam Sodium Medical Research Studies

Up-to-date List of Piperacillin Sodium And Tazobactam Sodium Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Piperacillin Sodium And Tazobactam Sodium Medical Research Studies

Rank Status Study
1 Recruiting Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
Condition: Primary Immune Deficiency
Intervention:
Outcome Measure: Objectives: We propose to evaluate patients who may have, or are suspected of having, inherited diseases of lymphocyte homeostasis and programmed Cell Death. Caspase-8-deficient patients illustrate the dual overlapping roles of certain molecules...
2 Recruiting Detection of Human Beta Cell Death in Type 1 Diabetes Mellitus (T1DM) by Methylation Specific Polymerase Chain Reaction (PCR)
Condition: Type 1 Diabetes Mellitus
Intervention: Procedure: Blood draw
Outcome Measures: Develop sensitive, specific, and quantitative methylation- specific PCR assays for the detection of human beta cell-specific DNA methylation patterns cells and the onset of metabolic dysregulation.;   Use the assays to detect beta cell destruction throughout the early time-course of type 1 diabetes mellitus
3 Recruiting Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
Conditions: Carcinoma, Intraductal, Noninfiltrating;   DCIS;   Ductal Carcinoma In Situ
Interventions: Drug: Chloroquine Standard Dose (500mg/week);   Drug: Chloroquine Low Dose (250mg/week);   Procedure: Breast Biopsy
Outcome Measures: Tumor response evaluated by RECIST criteria as measured by breast MRI.;   Evaluate the safety and dosing efficacy of chloroquine in the treatment of patients with DCIS.;   Evaluate the effect of therapy on the progenitor cell yield and invasive capacity ex vivo.;   Evaluate the effect of treatment on the proteomic and molecular cytogenetic profiles of the DCIS lesions.
4 Recruiting A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Condition: Non-small Cell Lung Carcinoma
Interventions: Drug: Pembrolizumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Pemetrexed;   Biological: Ipilimumab;   Drug: Erlotinib;   Drug: Gefitinib
Outcome Measures: Part II, Cohort G: Progression-Free Survival (PFS);   Part II, Cohort G: Objective Response Rate;   Part II, Cohort H: Objective Response Rate;   Part I, All Cohorts: the recommended Phase II dose for pembrolizumab in combination with chemotherapy or immunotherapy;   Part II, Cohort G: Overall survival (OS)
5 Not yet recruiting The Effect of Human Placental Explants and Pregnant Women Sera on Cancer Cells
Condition: Cancer
Intervention:
Outcome Measure: Cancer cell phenotype (in the laboratory)
6 Not yet recruiting Vinorelbine in Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Vinorelbine;   Other: Active Symptom Control
Outcome Measures: Overall Survival;   Progression Free Survival;   Number of serious adverse events reported;   BRCA1 status in blood and tumour samples
7 Recruiting Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Condition: HIV Infections
Interventions: Drug: BMS-936559;   Drug: Placebo for BMS-936559
Outcome Measures: Occurrence of a Grade 3 or greater adverse event (AE), including sign/symptom, lab toxicity, or clinical event that is definitely, probably, or possibly related to study treatment;   Occurrence of a Grade 1 or > AE of all incident adrenal insufficiency or adrenal crisis (confirmed), myocarditis, pneumonitis, uveitis, immune-mediated hyperthyroidism or hypothyroidism, that is definitely, probably, or possibly related to study;   Frequency of HIV-1 Gag-specific CD8 T-cells by intracellular staining for interferon (IFN)-gamma at baseline and after treatment (through Day 28);   HIV-1 RNA by single copy assay (SCA) at baseline and after treatment (through Day 28);   PK parameters from non-compartmental analysis (area under curve [AUC], Cmax, V, Tmax, CL/F, t1/2);   Exploratory pharmacodynamic parameters (Emax, EC50);   HIV-1 DNA at baseline and after treatment;   Programmed Cell Death 1 ligand 1 (PD-L1) receptor occupancy;   Proportion of total and HIV-1 gag-specific CD8 T-cells expressing programmed Cell Death 1 (PD-1), PD-L1, and other exhaustion markers;   CD107a mobilization and carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution of HIV-1 gag-specific CD8 T-cells;   Polyfunctionality of HIV-1 specific CD8 and CD4 T-cells;   CD38 and human leukocyte antigen-DR (HLA-DR) expression on CD8 T-cells;   Gene expression profiles in whole blood;   Detection of antibody to study treatment in plasma;   Occurrence of a Grade 3 or greater AE, including sign/symptom, lab toxicity, or clinical event that is definitely, probably, or possibly related to study treatment;   Occurrence of a Grade 1 or > AE of all incident adrenal insufficiency or adrenal crisis (confirmed), myocarditis, pneumonitis, uveitis, immune mediated hyperthyroidism or hypothyroidism, that is definitely, probably, or possibly related to study;   2-long terminal repeat (2LTR) circle DNA at baseline and after treatment;   Cell-associated HIV-1 RNA at baseline and after treatment;   RNA/DNA ratios in total CD4 cells at baseline and after treatment;   Expression of programmed Cell Death 1 ligand 2 (PD-L2) on dendritic cells and monocyte-derived macrophages
8 Unknown  Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.
Conditions: Brain Metastases;   Solid Tumors
Interventions: Drug: 2-(5-fluoro-pentyl)-2-methyl-malonic-acid ([18F]-ML-10);   Radiation: Stereotactic Radio-Surgery (SRS) therapy;   Procedure: Positron Emission Tomography
Outcome Measures: To assess the relationship between changes in 18FML10 uptake in the target lesions (PET/CT) obtained before and after radiotherapy (SRS), and changes of the lesions size (MRI, ~8w after SRS) in response to treatment, according to the WHO criteria;   Characterization of early alterations in the voxel-based 18FML10 uptake in the target lesion in response to the single fraction high-dose Stereotactic RadioSurgery, SRS. 18FML10 uptake at 24h after SRS and at baseline, before SRS, will be compared;   To identify parameters derived from the changes in 18FML10 uptake observed early after SRS that can discriminate responsive from non-responsive target lesions, and to estimate optimal cut-off values of this parameter (sensitivity and specificity);   To perform additional analyses for all other lesions with longest diameter ≥ 1.5 cm treated by SRS.
9 Recruiting A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)
Condition: Renal Cell Cancer
Interventions: Drug: Pembrolizumab;   Procedure: Surgical Resection
Outcome Measures: Number of participants with an adverse event;   Number of participants who discontinued treatment due to an adverse event;   Percentage of participants treated with pembrolizumab with a 2-fold or greater change from baseline in intratumoral lymphocytic infiltration;   Change from baseline in levels of gene expression of immune modulatory receptors in tumors of participants treated with pembrolizumab;   Change from baseline in number of T cells in tumors of participants treated with pembrolizumab;   Change from baseline in number of activated T cells in peripheral blood of participants treated with pembrolizumab;   Change from baseline in levels of programmed Cell Death 1 ligand 1 (PD-L1) protein in tumors of participants treated with pembrolizumab;   Change from baseline in levels of programmed Cell Death 1 ligand 2 (PD-L2) protein in tumors of participants treated with pembrolizumab
10 Recruiting Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Condition: Head and Neck Squamous Cell Carcinoma (HNSCC)
Intervention: Biological: pembrolizumab
Outcome Measures: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST 1.1);   Number of Participants Experiencing an Adverse Event (AE);   Number of Participants Discontinuing Study Drug Due to an AE;   ORR by RECIST 1.1 in Programmed Cell Death Ligand 1 (PD-L1)-Positive Participants;   ORR by Modified RECIST 1.1 in All Participants;   ORR by Modified RECIST 1.1 in PD-L1-Positive Participants;   ORR by Modified RECIST 1.1 in Human Papilloma Virus (HPV)-Positive Participants;   Progression-free Survival (PFS) in All Participants;   PFS in PD-L1-Positive Participants;   Overall Survival (OS) in All Participants;   OS in PD-L1-Positive Participants;   Response Duration in All Participants;   Response Duration in PD-L1-Positive Participants
11 Not yet recruiting MK-3475/BCG in High Risk Superficial Bladder Cancer
Condition: Bladder Cancer
Intervention: Drug: Intravenous MK-3475/ Intravesical BCG
Outcome Measures: safety (Grade and quantity of adverse events);   disease free state (cytoscopy);   Quality of Life
12 Recruiting Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia
Conditions: Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
Intervention: Other: laboratory biomarker analysis
Outcome Measures: Expression level and activation state of FLT3 protein, determined by Western blotting and FACS;   TKI sensitivity, determined by MTT and annexin V assays;   Baseline activation and inhibition of STAT5, AKT, and RAS-MAPK and other pathways, examined with Western blotting and phosphospecific antibodies;   Incidence of Cell Death in primary infant leukemia samples treated with sequenced combinations of chemotherapy and FLT3 TKI using MTT and annexin V binding assays and median effect analysis
13 Recruiting A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
Conditions: Carcinoma Neuroendocrine;   Small Cell Lung Carcinoma;   Malignant Epithelial Neoplasms
Interventions: Drug: Belinostat;   Drug: Cisplatin;   Drug: Etoposide
Outcome Measures: Safety and tolerability;   Markers of HDAC;   Tumor response;   miRNA and CGH;   Increased acetylation in PBMCs
14 Recruiting Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)
Condition: Brain Cancer
Interventions: Drug: Temozolomide;   Drug: Memantine;   Drug: Mefloquine;   Drug: Metformin
Outcome Measures: Maximum Tolerated Dose (MTD) Levels;   Progression Free Survival (PFS)
15 Recruiting A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: thioureidobutyronitrile
Outcome Measures: Maximum Tolerated Dose (MTD) of Kevetrin;   Dose Limiting Toxicities (DLT) of Kevetrin.;   Pharmacokinetic Profile of Kevetrin;   Change in tumor size;   Decrease in serum tumor marker;   Changes in the biomarker p21 in peripheral blood lymphocytes
16 Unknown  Pilot Investigation of Ultrasound Imaging and Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Locally-Advanced Breast Cancer Response to Neoadjuvant Treatment
Condition: Locally Advanced Breast Cancer
Intervention:
Outcome Measure:
17 Recruiting Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Olaparib
Outcome Measures: Progression-free survival;   Safety;   Objective response rate;   Overall survival;   Change in tumour volume reduction;   Tolerability;   Feasibility
18 Recruiting A Phase I Trial of AZD3965 in Patients With Advanced Cancer
Conditions: Adult Solid Tumor;   Prostate Cancer;   Gastric Cancer;   Diffuse Large B Cell Lymphoma
Intervention: Drug: AZD3965
Outcome Measures: A recommended safe and biologically active dose of AZD3965 for evaluation in Phase II trials.;   Pharmacokinetic profile of AZD3965 in plasma including area under the plasma concentration-time curve (AUC) maximum concentration (Cmax), time to maximum concentration (Tmax) and elimination half-life (T1/2);   Changes in the Cell Death markers M65,M30 and nuclear DNA (nDNA);   Objective tumour responses to AZD3965 according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measured after every 2 cycles
19 Not yet recruiting Alisertib in Malignant Mesothelioma
Conditions: Lung Cancer;   Mesothelioma
Intervention: Drug: Alisertib
Outcome Measures: Disease Control Rate (DCR);   Response Rate
20 Unknown  Characterization of the Mechanisms of Resistance to Azacitidine
Condition: Myelodysplastic Syndromes or Acute Myeloid Leukemia With Multilineage Dysplasia
Intervention:
Outcome Measure:

These studies may lead to new treatments and are adding insight into Piperacillin Sodium And Tazobactam Sodium etiology and treatment.

A major focus of Piperacillin Sodium And Tazobactam Sodium research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Piperacillin Sodium And Tazobactam Sodium